ZA200302914B - Novel anticholinergic agents that can be used as medicaments and method for the production thereof. - Google Patents
Novel anticholinergic agents that can be used as medicaments and method for the production thereof. Download PDFInfo
- Publication number
- ZA200302914B ZA200302914B ZA200302914A ZA200302914A ZA200302914B ZA 200302914 B ZA200302914 B ZA 200302914B ZA 200302914 A ZA200302914 A ZA 200302914A ZA 200302914 A ZA200302914 A ZA 200302914A ZA 200302914 B ZA200302914 B ZA 200302914B
- Authority
- ZA
- South Africa
- Prior art keywords
- denotes
- methyl
- fluorine
- general formula
- ethyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 15
- 239000000812 cholinergic antagonist Substances 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 238000000034 method Methods 0.000 title description 8
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 56
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 52
- 150000001875 compounds Chemical class 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 42
- 150000002431 hydrogen Chemical class 0.000 claims description 33
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 30
- 239000011737 fluorine Chemical group 0.000 claims description 30
- 229910052731 fluorine Chemical group 0.000 claims description 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- -1 methyloxy, ethyloxy Chemical group 0.000 claims description 17
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 13
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 239000000460 chlorine Substances 0.000 claims description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- CTCCHKSGCBWINA-UHFFFAOYSA-N 2-methoxyethoxy hypofluorite Chemical compound COCCOOF CTCCHKSGCBWINA-UHFFFAOYSA-N 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 5
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 4
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 claims description 3
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 claims description 3
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 101000800807 Homo sapiens Tumor necrosis factor alpha-induced protein 8 Proteins 0.000 claims 1
- 208000019255 Menstrual disease Diseases 0.000 claims 1
- 206010040741 Sinus bradycardia Diseases 0.000 claims 1
- 102100033649 Tumor necrosis factor alpha-induced protein 8 Human genes 0.000 claims 1
- 208000026723 Urinary tract disease Diseases 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 11
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- FIMXSEMBHGTNKT-UHFFFAOYSA-N Scopine Natural products CN1C2CC(O)CC1C1C2O1 FIMXSEMBHGTNKT-UHFFFAOYSA-N 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical class C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 4
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical group O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 4
- FIMXSEMBHGTNKT-RZVDLVGDSA-N scopine Chemical compound C([C@@H]1N2C)[C@H](O)C[C@@H]2[C@@H]2[C@H]1O2 FIMXSEMBHGTNKT-RZVDLVGDSA-N 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 3
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 3
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000026030 halogenation Effects 0.000 description 3
- 238000005658 halogenation reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910052735 hafnium Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10050994A DE10050994A1 (de) | 2000-10-14 | 2000-10-14 | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200302914B true ZA200302914B (en) | 2003-11-14 |
Family
ID=7659808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200302914A ZA200302914B (en) | 2000-10-14 | 2003-04-11 | Novel anticholinergic agents that can be used as medicaments and method for the production thereof. |
Country Status (38)
Country | Link |
---|---|
EP (2) | EP1325001B1 (ru) |
JP (2) | JP4109106B2 (ru) |
KR (1) | KR100830359B1 (ru) |
CN (1) | CN1275962C (ru) |
AR (1) | AR035589A1 (ru) |
AT (1) | ATE259805T1 (ru) |
AU (2) | AU2002213975B2 (ru) |
BG (1) | BG66225B1 (ru) |
BR (1) | BR0114635A (ru) |
CA (1) | CA2425557C (ru) |
DE (2) | DE10050994A1 (ru) |
DK (1) | DK1325001T3 (ru) |
EA (1) | EA005816B1 (ru) |
EC (1) | ECSP034542A (ru) |
EE (1) | EE05179B1 (ru) |
ES (1) | ES2215147T3 (ru) |
HK (1) | HK1060566A1 (ru) |
HR (1) | HRP20030278B1 (ru) |
HU (1) | HUP0301203A3 (ru) |
IL (2) | IL155334A0 (ru) |
ME (1) | MEP39908A (ru) |
MX (1) | MXPA03003160A (ru) |
MY (1) | MY127144A (ru) |
NO (1) | NO328207B1 (ru) |
NZ (1) | NZ525836A (ru) |
PE (1) | PE20020433A1 (ru) |
PL (1) | PL207311B1 (ru) |
PT (1) | PT1325001E (ru) |
RS (1) | RS50464B (ru) |
SA (1) | SA01220414B1 (ru) |
SI (1) | SI1325001T1 (ru) |
SK (1) | SK287138B6 (ru) |
TR (1) | TR200400376T4 (ru) |
TW (1) | TWI306098B (ru) |
UA (1) | UA73804C2 (ru) |
UY (1) | UY26958A1 (ru) |
WO (1) | WO2002032899A1 (ru) |
ZA (1) | ZA200302914B (ru) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10200943A1 (de) * | 2002-01-12 | 2003-07-24 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Scopinestern |
DE10203753A1 (de) * | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7405224B2 (en) | 2002-01-31 | 2008-07-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions |
US7417051B2 (en) | 2002-04-12 | 2008-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising betamimetics and a novel anticholinergic |
PT1497289E (pt) * | 2002-04-12 | 2005-11-30 | Boehringer Ingelheim Pharma | Farmaco contendo betamimeticos e um novo anticolinergico |
DE10216429A1 (de) * | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
DE10256317A1 (de) * | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Betamimetika und ein neues Anticholinergikum |
US7084153B2 (en) | 2002-04-12 | 2006-08-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising steroids and a novel anticholinergic |
DE10224091A1 (de) * | 2002-05-31 | 2003-12-11 | Boehringer Ingelheim Pharma | Technisches Verfahren zur Herstellung von Tropenol |
DE60310730T2 (de) * | 2002-07-09 | 2007-05-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
DE10230751A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern |
DE10230750A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholonergika und NK1-Rezeptor-Antagonisten |
DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
CN1674887A (zh) * | 2002-08-14 | 2005-09-28 | 贝林格尔英格海姆法玛两合公司 | 含抗胆碱能剂的吸入用的气雾剂制剂 |
DE10237739A1 (de) * | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
DE10317461A1 (de) | 2003-04-16 | 2004-10-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung |
US7332175B2 (en) | 2003-05-27 | 2008-02-19 | Boehringer Ingelheim International Gmbh | Long-acting drug combinations for the treatment of respiratory complaints |
DE10323966A1 (de) * | 2003-05-27 | 2004-12-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
DE10331350A1 (de) * | 2003-07-11 | 2005-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation enthaltend ein neues Anticholinergikum |
US7273603B2 (en) | 2003-07-11 | 2007-09-25 | Boehringer Ingelheim International Gmbh | HFC solution formulations containing an anticholinergic |
US7462367B2 (en) | 2003-07-11 | 2008-12-09 | Boehringer Ingelheim International Gmbh | Anticholinergic powder formulations for inhalation |
CA2533791C (en) * | 2003-07-28 | 2012-05-22 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising betamimetics and an anticholinergic agent |
CA2533786A1 (en) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
ES2326320T3 (es) * | 2003-07-28 | 2009-10-07 | Boehringer Ingelheim International Gmbh | Medicamentos para inhalacion que comprenden esteroides y nuevo ester del acido fluorencarboxilico. |
JP2007500676A (ja) * | 2003-07-31 | 2007-01-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤 |
EP1504756A1 (en) * | 2003-08-06 | 2005-02-09 | Kyowa Hakko Kogyo Co., Ltd | Medicament compositions comprising a heterocyclic compound and an anticholinergic |
DE10345065A1 (de) * | 2003-09-26 | 2005-04-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum |
CA2547394A1 (en) * | 2004-01-09 | 2005-07-28 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on a scopineester and nicotinamide derivatives |
US20050186175A1 (en) * | 2004-02-20 | 2005-08-25 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on benzilic acid esters and soluble TNF receptor fusion proteins |
US7507745B2 (en) | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
WO2005079794A1 (en) * | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on anticholinergics and pegsunercept |
DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
ATE427108T1 (de) * | 2004-08-11 | 2009-04-15 | Boehringer Ingelheim Pharma | Anticholinergika enthaltende arzneimittel zur behandlung von krankheiten der ableitenden harnwege |
DE102004056578A1 (de) * | 2004-11-23 | 2006-05-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Formoterol und ein Steroid |
CA2597942A1 (en) * | 2005-02-16 | 2006-08-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising anticholinergics and etiprednol |
CA2600636A1 (en) * | 2005-03-09 | 2006-09-14 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors |
CA2609429A1 (en) * | 2005-05-31 | 2006-12-07 | Boehringer Ingelheim International Gmbh | Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor |
EP1898894A1 (en) * | 2005-06-17 | 2008-03-19 | Boehringer Ingelheim International GmbH | Mrp iv inhibitors for the treatment of respiratory diseases |
DE102005030733A1 (de) | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
JP5270343B2 (ja) | 2005-08-15 | 2013-08-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベータミメティックスの製造方法 |
US20090221664A1 (en) | 2005-10-19 | 2009-09-03 | Abhijit Ray | Pharmaceutical compositions of muscarinic receptor antagonists |
DE102005055957A1 (de) * | 2005-11-24 | 2007-07-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum |
DE102005055963A1 (de) * | 2005-11-24 | 2007-07-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum |
DE102005055961A1 (de) * | 2005-11-24 | 2007-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum |
DE502007006951D1 (de) | 2006-08-07 | 2011-05-26 | Boehringer Ingelheim Pharma | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
US20080207659A1 (en) | 2007-02-15 | 2008-08-28 | Asit Kumar Chakraborti | Inhibitors of phosphodiesterase type 4 |
MX2009009793A (es) | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. |
ES2569359T3 (es) | 2007-07-06 | 2016-05-10 | Vectura Delivery Devices Limited | Inhalador |
CA2688669A1 (en) * | 2007-07-18 | 2009-01-22 | Boehringer Ingelheim International Gmbh | New combinations for the treatment of respiratory diseases |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
EP2082771A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082766A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Blister Strip Coil Forming |
EP2082768A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082772A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082767A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2111861A1 (en) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
WO2010112358A2 (de) | 2009-03-31 | 2010-10-07 | Boehringer Ingelheim International Gmbh | Verfahren zur beschichtung einer oberfläche eines bauteils |
JP5763053B2 (ja) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アダプタ、吸入器具及びアトマイザ |
GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
JP5658268B2 (ja) | 2009-11-25 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
EA026241B1 (ru) | 2009-11-25 | 2017-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Распылитель |
JP5874724B2 (ja) | 2010-06-24 | 2016-03-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
WO2012130757A1 (de) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medizinisches gerät mit behälter |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
EP2934544B1 (en) | 2012-12-21 | 2018-11-07 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical formulation comprising ciclesonide |
US9918995B2 (en) | 2012-12-21 | 2018-03-20 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for the treatment of airway disease in horses |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
EP2835146B1 (en) | 2013-08-09 | 2020-09-30 | Boehringer Ingelheim International GmbH | Nebulizer |
DK3139979T3 (da) | 2014-05-07 | 2023-10-09 | Boehringer Ingelheim Int | Enhed, forstøver og fremgangsmåde |
NZ724449A (en) | 2014-05-07 | 2022-01-28 | Boehringer Ingelheim Int | Nebulizer and container |
EP3139984B1 (en) | 2014-05-07 | 2021-04-28 | Boehringer Ingelheim International GmbH | Nebulizer |
LT3157522T (lt) | 2014-06-18 | 2019-11-25 | Boehringer Ingelheim Vetmedica Gmbh | Muskarininiai antagonistai ir jų deriniai, skirti arklių kvėpavimo takų ligos gydymui |
EP3344628B9 (en) * | 2015-09-04 | 2021-06-30 | Janssen Pharmaceutica NV | Therapeutic compounds and synthesis |
CN113292574B (zh) * | 2020-02-21 | 2022-05-03 | 四川大学 | 一类手性多环的托品烷化合物及其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4003270A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgase und ihre verwendung in arzneimittelzubereitungen |
DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
-
2000
- 2000-10-14 DE DE10050994A patent/DE10050994A1/de not_active Withdrawn
-
2001
- 2001-09-28 AU AU2002213975A patent/AU2002213975B2/en not_active Expired
- 2001-09-28 NZ NZ525836A patent/NZ525836A/en not_active IP Right Cessation
- 2001-09-28 WO PCT/EP2001/011226 patent/WO2002032899A1/de active IP Right Grant
- 2001-09-28 PL PL360673A patent/PL207311B1/pl not_active IP Right Cessation
- 2001-09-28 AT AT01982374T patent/ATE259805T1/de active
- 2001-09-28 HU HU0301203A patent/HUP0301203A3/hu unknown
- 2001-09-28 KR KR1020037005256A patent/KR100830359B1/ko not_active IP Right Cessation
- 2001-09-28 TR TR2004/00376T patent/TR200400376T4/xx unknown
- 2001-09-28 AU AU1397502A patent/AU1397502A/xx active Pending
- 2001-09-28 BR BR0114635-1A patent/BR0114635A/pt not_active Expired - Fee Related
- 2001-09-28 UA UA2003054186A patent/UA73804C2/uk unknown
- 2001-09-28 MX MXPA03003160A patent/MXPA03003160A/es active IP Right Grant
- 2001-09-28 ES ES01982374T patent/ES2215147T3/es not_active Expired - Lifetime
- 2001-09-28 EP EP01982374A patent/EP1325001B1/de not_active Expired - Lifetime
- 2001-09-28 DE DE50101524T patent/DE50101524D1/de not_active Expired - Lifetime
- 2001-09-28 IL IL15533401A patent/IL155334A0/xx active IP Right Grant
- 2001-09-28 CN CNB018171443A patent/CN1275962C/zh not_active Expired - Lifetime
- 2001-09-28 ME MEP-399/08A patent/MEP39908A/xx unknown
- 2001-09-28 CA CA002425557A patent/CA2425557C/en not_active Expired - Lifetime
- 2001-09-28 SI SI200130085T patent/SI1325001T1/xx unknown
- 2001-09-28 SK SK435-2003A patent/SK287138B6/sk not_active IP Right Cessation
- 2001-09-28 DK DK01982374T patent/DK1325001T3/da active
- 2001-09-28 RS YUP-295/03A patent/RS50464B/sr unknown
- 2001-09-28 PT PT01982374T patent/PT1325001E/pt unknown
- 2001-09-28 EP EP03023933A patent/EP1382606A3/de not_active Withdrawn
- 2001-09-28 JP JP2002536281A patent/JP4109106B2/ja not_active Expired - Lifetime
- 2001-09-28 EE EEP200300151A patent/EE05179B1/xx not_active IP Right Cessation
- 2001-09-28 EA EA200300459A patent/EA005816B1/ru not_active IP Right Cessation
- 2001-10-02 SA SA01220414A patent/SA01220414B1/ar unknown
- 2001-10-10 UY UY26958A patent/UY26958A1/es not_active Application Discontinuation
- 2001-10-12 AR ARP010104785A patent/AR035589A1/es active Pending
- 2001-10-12 PE PE2001001018A patent/PE20020433A1/es not_active Application Discontinuation
- 2001-10-12 TW TW090125220A patent/TWI306098B/zh not_active IP Right Cessation
- 2001-10-12 MY MYPI20014765A patent/MY127144A/en unknown
-
2003
- 2003-03-28 BG BG107688A patent/BG66225B1/bg active Active
- 2003-04-07 EC EC2003004542A patent/ECSP034542A/es unknown
- 2003-04-10 IL IL155334A patent/IL155334A/en not_active IP Right Cessation
- 2003-04-11 HR HR20030278A patent/HRP20030278B1/xx not_active IP Right Cessation
- 2003-04-11 ZA ZA200302914A patent/ZA200302914B/en unknown
- 2003-04-11 NO NO20031693A patent/NO328207B1/no not_active IP Right Cessation
-
2004
- 2004-05-20 HK HK04103582A patent/HK1060566A1/xx not_active IP Right Cessation
-
2008
- 2008-02-14 JP JP2008033492A patent/JP2008120834A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200302914B (en) | Novel anticholinergic agents that can be used as medicaments and method for the production thereof. | |
JP5134756B2 (ja) | スコピンエステルの調製方法 | |
JP5629420B2 (ja) | 新規な抗コリン作用薬、それらの調製方法及び医薬組成物としてのそれらの使用 | |
JP4484522B2 (ja) | 新規フルオレンカルボン酸エステル、その製造方法及び薬物としてのその使用 | |
US7569581B2 (en) | Anticholinergics which may be used as medicaments as well as processes for preparing them | |
AU2003206760B8 (en) | Anticholinergic agents, method for producing the same and use thereof as medicaments | |
JP4554936B2 (ja) | M3アンタゴニストとしてのトロペノール及びスコピンのキサンテンカルボン酸エステル、その製造方法及び薬物としてのその使用 | |
KR20030062439A (ko) | 항콜린제인 티오트로퓸 브로마이드의 제조방법 | |
CZ281509B6 (cs) | Nové estery bi- a tricyklických aminoalkoholů, způsob výroby a farmaceutické prostředky s jejich obsahem | |
CA2482637C (en) | New esters of hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions | |
EP2552912B1 (en) | Synthesis method for producing tiotropium bromide | |
CA2476746A1 (en) | Difurylglycolic acid tropenol esters used as anticholinesterase drugs | |
JPH06306076A (ja) | ベンズアミド誘導体 | |
ZA200404366B (en) | Novel fluorene carboxylic acid esters methods for the production thereof and use of the same as pharmaceuticals |